Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity

Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells

(2011) L. Wang et al.   HAEMATOLOGICA

Pericytes and vessel maturation during tumor angiogenesis and metastasis

(2010) Ahmad Raza et al.   AMERICAN JOURNAL OF HEMATOLOGY

Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma

(2010) Jia Ruan et al.   CANCER

Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma

(2010) Richard R. Furman et al.   CANCER

Epstein–Barr virus as a prognostic factor inde novonodal diffuse large B-cell lymphoma

(2010) Domingo Morales et al.   LEUKEMIA & LYMPHOMA

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

(2009) H. E. Heslop et al.   BLOOD

Epstein-Barr virus–positive B-cell lymphoma of the elderly at a United States tertiary medical center: an uncommon aggressive lymphoma with a nongerminal center B-cell phenotype

(2009) Sarah E. Gibson et al.   HUMAN PATHOLOGY

Epstein-Barr virus–positive diffuse large B-cell lymphoma in elderly patients is rare in Western populations

(2009) Sylvia Hoeller et al.   HUMAN PATHOLOGY

Epstein-Barr virus positive diffuse large B-cell lymphoma of the elderly

(2009) Hannah H. Wong et al.   LEUKEMIA & LYMPHOMA

A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108

(2009) Alison T. Stopeck et al.   LEUKEMIA & LYMPHOMA

Pronostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature

(2009) Semra Paydas et al.   LEUKEMIA RESEARCH

Anti-angiogenic strategies will be a revolution in lymphoma?

(2009) Semra Paydas   LEUKEMIA RESEARCH

Age-related EBV-associated B-cell lymphoproliferative disorders: Diagnostic approach to a newly recognized clinicopathological entity

(2009) Yoshie Shimoyama et al.   PATHOLOGY INTERNATIONAL

Expression of protease-activated receptor-2 (PAR-2) in patients with nasopharyngeal carcinoma: Correlation with clinicopathological features and prognosis

(2009) Zhi Li et al.   PATHOLOGY RESEARCH AND PRACTICE

mTOR inhibitor monotherapy is insufficient to suppress viremia and disease progression in Epstein-Barr virus-driven lymphoproliferative disorders (EBV-LPD)

(2008) Shernan G. Holtan et al.   AMERICAN JOURNAL OF HEMATOLOGY

Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma

(2008) J. Ruan et al.   ANNALS OF ONCOLOGY

Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B

(2008) Sonali M. Smith et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: Low-dose metronomic, multidrug therapy

(2008) Morton Coleman et al.   CANCER

Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas

(2008) Semra Paydas et al.   LEUKEMIA RESEARCH

Homage to Judah Folkman

(2008) B. A. Chabner et al.   ONCOLOGIST